Chris Marlett
Chief Executive Officer and Co-Founder
Replay available
MDB Capital Holdings (NASDAQ:MDBH) Q2 2026 earnings call, held 2026-08-13. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/mdb-capital-holdings-llc-mdbh-q2-2026-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Welcome everyone to the MDB Capital Holdings second quarter and first half 2026 update conference call. Thanks so much for joining us today. At this time, all participants are in listen-only mode. Before we begin the formal presentation, I'd like to remind everyone of several important things. Today's conference call is being recorded. A Q&A session will follow the formal presentation. If you have questions during the presentation, you can type them into the Q&A chat to be answered during the Q&A session. Remember, questions can only be seen by the moderator. Please remember that statements made on this call and webcast may contain provisions, estimates, or other information that might be considered forward-looking.
0:54 While these forward-looking statements represent our current judgment on what the future holds, They're subject to risk and uncertainties that could cause actual results to differ materially. You're cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Also, please beware that we are not obligating ourselves to revise or publicly release results or any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we'll attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading Risk Factors.
1:49 A press release detailing these results, which crossed the wire this afternoon, is available in the Investor Relations section of our website, mdb.com. A replay of this call will also be provided later on MDB.com. Your host today is Chris Marlett, Chief Executive Officer and Co-Founder of MDB Capital Holdings. Chris will be joined later by George Brandon, MDB President and Head of Community Development. Chris will lead a business update for the quarter ending June 30, 2026 and subsequent developments. So at this time, I'd like to turn the call over to Chris Marlett. Chris?
2:30 Thanks, Tony. Well, great. Let's get the deck up here. Great. Thanks again, Tony. Everyone, thank you for joining today. I wanted to thank you all for joining. It's been... Christopher Marlett, Jeremy William James So, quick overview of the agenda, really. I wanted to talk about sort of the backdrop of the micro-cap markets and what it means for us and really our plan for maximizing our core assets. I don't think that we've done a good enough job about talking about our core assets. So, I'd like to change up the presentations occasionally to basically give you a different way of looking at it, understanding what we've built at MDB and what we think the value is.
3:46 Those four core assets, some of you might know about, but I'll talk a little bit more as we get into the presentation. We've also got real financial discipline. When you look at our financial statements, it's very hard to really discern exactly what's going on. I'm trying to simplify that so that you understand that we have really a core operating platform that we can make very efficient that has a lot of leverage. and so our objective is to provide that leverage without any real dilution. That's the key. With all of our companies, whether it be a portfolio company that we're trying to help to get to commercialization and value creation or whether it's MDB doing the exact same thing. It's called leverage without dilution. That's sort of what's inherent in all the companies that we get behind.
4:35 So not to use as an excuse, but really Thank you very much. If you look at even venture funding, such a huge percentage of it is going to these very, very large companies. And the small companies are really languishing, not only in sort of the public markets, but also in the private markets. And so when you look at the headline numbers of the anthropics and open AIs getting funded, the money moving around is really staggering.
5:35 But then when you look underneath it and you look at these small companies, it's a very, very different picture. So when you look at overall funding, about 70% of all funding has gone towards AI-focused companies. And while we have what I think are some great, you know, AI-based companies in our portfolio, I don't know that that translates into, you know, total valuation. But I do believe... We've got a great shot of our sort of AI-enabled companies getting into that trend, and that's really what we're focused on for the past year. So if you really look at it, both ends of the barbell are very different. And sort of all these kind of tiny companies, both in the traditional venture world and in the public venture world, are sort of being neglected.
6:28 and so when you look at these small IPOs, we've talked about it before, but the number of public companies has been dropping in the U.S. and so we've gone from roughly 8,000 public companies around 2,000 to less than 4,000 today and even though there's 1,000 companies sort of in this sub-$200 million market value area, It only comprises about 2% of the total market capitalization. So if you figure 25% of the companies are in this space, yet it only comprises 2% of the equity market value. And so these institutional investors, not that they necessarily drive stock prices, but it's just really an indicator of fund flows.
7:13 What we found is once a company gets to a certain market value, and institutions start to participate, Thank you for joining us. There's a huge difference between a company trading at a $100 million valuation and a $500 million valuation. You'll see vast valuation differences. And I think the game is as it gets bigger, it gets a wider audience of people looking at it.
7:58 So even though you'll say, oh, wow, the small cap indices rebounded sharply in the second quarter, The average market cap of, let's say, the Russell microcap is over $2.5 billion, which is a totally different market than the market we're playing in. Again, it's just an artifact that we haven't seen before historically in the development of MDB. It's sort of gone to an extreme level. We do think that at some point money's rotate, money, you know, Money typically rotates the value at some point or where there's the most upside. We actually think if the really big end of the spectrum, today we made new highs, that if that segment got pressured, we don't really see that as a real risk for our segment. We actually think that money will still have to rotate somewhere.
8:52 And so we do think that if the big market comes down, it's not necessarily going to... The small ones that we think are actually sort of on the floor. So we look at it as it's kind of hard to fall off the floor. Again, no promises, plenty of risk factors there, but I just think that that's our view of where the markets are and what we see as the potential opportunity as money rotates again. So what does that mean for us and what we're doing? You know, we're not happy with where we're at. We certainly didn't go public with the idea of, you know, this happening and our stock being down from where we took the company public.
9:38 But, you know, when you think about when we went public, the last three companies we had taken public before we had gone public all went to billion dollar valuations. And so we expected that in that kind of marketplace, you know, our shareholders would do Thank you very much. and then next thing you know, you know, things changed. I mean, if you look at something like a company like Pulse Biosciences that we've, that we took, you know, we really started the company, formed it, took it public, you know, the stock went, you know, we took it public at four, it went to 40 or high 30s, came down again, went to, you know, the 40, 40 again, down to a dollar.
10:38 Everybody thought, you know, it was left for dead and today it just made another new high at $46 a share. So, It's, again, it can be super volatile and fortunes change with these things. And it's really amazing to see what's happened over the last five, six years in this micro-cap sector. I can't emphasize any more that we feel, you know, you're sort of as good as your last performance. And Thank you for joining us. But the price is the price, right? And you guys are looking at the prices and saying, wow, you know, maybe, you know, these guys at MDB aren't so smart.
11:48 Our perspective is we've been through this before. And again, I sit here the same way you do. I don't like seeing my stock being down. I certainly don't like the fact that, you know, we sold this to other people and the stock is down. But it doesn't change how we feel about what we've developed. We still feel very bullish about what we've developed. and we also feel very bullish about our ability to create new companies in a lot of value and we think that we've built a great team, a great platform and a great process for doing that but you've got to have winners and that's, you know, a part of that is the rotation of the asset class and part of it is picking the right things and making sure they get to commercialization.
12:33 So really what we're doing is we're working very hard to realize the potential of each asset And that's where we sort of redoubled our focus on our existing portfolio to make sure they get to those key value inflection points. So, you know, what we've done, we talked about, you know, scaling from one launch every 18 months to three to five, you know, what we talked about year end, we talked about AI transforming our sourcing and diligence and our launch models. We still believe all of that. and building a venture portfolio so that we can broaden the risk amongst many companies. And much of our operating expenses have been invested in those big ideas like PatentVest and like our credit platform that we believe are smart investments.
13:27 As of right now, what we're looking at is, okay, right now going out and launching new companies is great, We're still looking for new companies, want to launch new companies, but monetizing our four core assets is really important. And so when you look at whether it's Public Ventures, PatentVest, X-Resigns, and Pollux, we see great potential in all those platforms, and we're in the process of really doubling down to make sure that those four assets get to a value inflection point. Our plan has never been, after going public, to ever really dilute the MDB shareholders. We're not looking to raise more money. We're not looking to go out and spend more money. As we said, nothing's changed from when we started MDB.
14:12 We want to distribute the value of those assets as we create them. But more importantly, we want to run now with this marketplace, it's not so much let's be aggressive and step on the gas. How do we run a very lean platform? How do we run this thing on $5 to $6 million a year, but still not only monetize the companies we have that have had historic billion-dollar leverage, but create new ones in a very cost-efficient manner? That's what we did before we went public, and our big idea of scaling those launches is is the timing is just not right. And we do think that environment will change and when it does change and we can go back to saying, okay, can we do more of them? But right now we don't need to do more.
15:05 We just need to monetize and leverage the ones that we've done and take a very, go back to a rifle shot approach until the environment is better for what we do. So I'll delve more into each one of these companies and tell you what we see and why we're excited about them as we've always been and drill down on those and a little bit more on our results. So public ventures, we always looked at self-clearing as a really important thing as these markets transform. A lot of what's happened in the securities markets is things have transformed from companies getting funded with traditional institutional investors at the low end to being heavily influenced by influencers.
16:01 We've seen money shifts to platforms like Robinhood and others that are much more momentum-based, much more different. and sort of your core fundamental bottoms-up investors in the microcap space. So we think that having a platform that can respond to that was very important. That's why we started Public Ventures. We got this up and running. It was a really great effort by our team to get this up and going. And it was about a five-year effort. It wasn't easy. We built it on a very, very lean budget. We built our back office in Latin America, which we think is super valuable to be able to support the platform. As many of you who are clients of MDB know that you can always pick up the phone, get somebody to make a trade for you or actually give you good customer service.
16:53 That's not an easy thing to do in this world today. And we built that and got it up and running. But that being said, we're not really leveraging it. In other words, if we're not launching a lot of companies, if we're not putting out four or five new companies a year and building that marketplace, then what we build actually has value. And so we're looking to partner it with somebody else out there that has a broader platform and can really use it and really enables us to focus on what we do, where all the leverage is, is launching big ideas. So we've been in discussions now with several parties, currently about four or five parties, and I think we'll be probably a few more. We've actually received some interest, letters of intent to do partnerships or even sales of the platform. So we're in the midst of that. I do think that we want to try and get something wrapped up in the next quarter. And I think there's a very good chance of that with the folks that we are talking about. We're excited to announce how that public clearing or the public venture or clearing platform can create more value by offering a much broader platform.
18:11 To our knowledge, there's no querying platforms really for sale or for partner right now. So currently, if you look at the discrete querying platforms that are out there today, there's about 100 of them. And we're one of 100, but so many of them are owned by the household names that you're familiar with. And so it's a unique opportunity for a lot of different types of people to to do that. I also think that what we do in investment banking, public venture, you know, some might call it crowdfunding, is attractive to a lot of different people. And we're just trying to find the best fit for MDB so that longer term, as we create new big ideas, we have a great platform and great partner to launch those with.
19:01 Pat Vest. So, you know, AI took us by surprise. to a certain degree. Again, it doesn't seem like that should be a surprise, but if you look at the realization that we hit at the end of the year was AI was changing very rapidly. Not only was the capabilities of AI changing very rapidly, but we saw a lot of the AI platforms being very commoditized. And what we're seeing is that AI... A lot of people were investing heavily in software development, and we were seeing that, geez, what's going to get commoditized in this space? And what we realized was the platform we had built at Patinvest was really unbelievably well positioned to pair with AI to build the law firm of the future, the patent law firm of the future.
19:56 And so we have pivoted our strategy quite dramatically to respond to the realization of that. And so there has been, as you've seen, a whole host of legal tech firms out there getting funded. It's now turned into a mega value market. Just four or five months ago, things like Harvey AI and these things that are serving law firms getting valued at several billions of dollars of value. But what's even more interesting about patent law, it's very different than traditional law is that it is a federal only practice. And so that's why we made the decision to start what we call an AVS law firm in the state of Arizona, which enables us to be an owner of a law firm and bring in business processes that are critical to lawyers to providing great patent work. And so this is an exciting time to build a home for great patent lawyers and it really makes a lot more sense for those patent lawyers to operate not in a traditional law firm structure that exists today.
21:18 And so we're super excited because what we're effectively doing is bringing our team of people with best in class AI processes to complete the workflow The patent lawyers shouldn't be doing, whether that's associate work, whether that's paralegal work, whether that's foreign filings. We can do that and basically take these great patent lawyers that are the brilliant minds and provide the platform that they need that works for them that's very different than what they may be experiencing in a small law firm that has limited resources or a very large law firm that That's the real story with what AI is going to enable.
22:03 Great lawyers are still going to get paid for their value, but Thank you for joining us. was recently funded at a $750 million pre-money valuation in the VC community. So we see that the logic of pairing ABS law with a law firm, a federal practice, just like they did in immigration law, but in a much bigger market than immigration law, could have huge strategic value. And so Javier Chamorro, who's been running that platform, It's done a great job along with the team to basically put together a great strategy.
23:34 We're out going to be executing a financing for that company to get it off the balance sheet of or I should say off the balance sheet. We're going to get it spun out as an independent entity where MDB is no longer funding the development. It'll be funded by independent investors. We're giving independent investors the opportunity to invest in PatentVest and and then participate in the growth of this platform that we think is truly innovative and is the future of patent law. Exozymes. So Exozymes has really been making an unbelievable transformation and I think that one of the things that's most misunderstood about Exozymes is that since we took the company public, People had not seen real commercial traction. And I think that that was a bit of misdirection.
24:34 And I think that what we were focused on was pivoting Exozymes to seeing that we could scale manufacturing because the bane of synthetic biology is it didn't scale. You had companies who created multi-billion dollar valuations like Ginkgo and Amherst and others that were public. and they made great announcements. They announced a lot of commercial deals, but they couldn't deliver. They couldn't deliver on manufacturing. And so we felt like we had to go out and make sure that we could deliver on that and while also looking for all the molecules where we can really, really get huge valuation inflection. And so that started with NCT, but I think the great news is now we have several other molecules, which we've talked about, and I think will be talked about by Exozymes in their conference call next week, that really broaden our ability to bring in commercial partners. I also believe that they are very close to executing relationship with contract manufacturers or one manufacturer as a strategic partner that could effectively make all of the small molecules that they're developing. So we can take the thing that's really held back synthetic biology, the manufacturing thing off the table with multiple compounds, which now opens up the ability to have real
26:07 commercial Thank you very much. Those commercial relationships will have a lot more value and could drive, you know, what we always believed, multi-billion dollar value, just like these other companies did. And so, you know, stay tuned. I think this is really a great time for Exozymes. It's been a long road, but we think we're very close to seeing those very tangible commercial collection points that will bring value to Exozymes and our portfolio.
27:08 and Pollux. Pollux is really getting to an exciting point in time. So, you know, I think that the company is very close to filing its registration statement for the IPO. And, you know, it's quite simply potentially one of the most earth shattering developments in diabetes. And what we're, you know, the reason we funded Pollux is very simple. We believe that this drug has a reasonably good shot at enabling beta cell expansion, which is insulin production, increasing insulin production, whether it be in a type 1 or type 2 diabetic. We believe that when you look at that and you do that at a very early stage, the implications to the diabetes and obesity wars that are happening in pharma right now is really earth shattering because This could be the core differentiator for all of these GLP-1 platforms or any of the other cocktails that are happening in this arena, which basically is completely synergistic.
28:18 And not only is our drug very synergistic with GLP-1s in preclinical models, but it also effectively, as you increase beta cell production, You create a whole different metabolic profile. And so we're very excited about it. And I think we're getting very close to demonstrating that it's safe. And that core value inflection point, which is beta cell production, we believe big pharma is going to have to take notice. And we see, again, huge valuation inflection potential.
29:03 very much like we had in prevention which we started with the same folks that we started Pilex with. So we had the first disease modifying type 1 diabetes drug at prevention. The size of the market with this dwarfs what prevention's discovery was. So we're super excited. We think that that data will start to play out in the early part of 2027. I think that everything is on track to our knowledge with clinical trial and I think they're going to be coming out with their own update very quickly and we'll be getting close to the IPO in the fourth quarter of this year and our hope is that this could be not only groundbreaking for patients but Groundbreaking from a value inflection point for Pollux and for MDB.
30:05 So when you look at the core four positions, we have 4.1 million shares plus some warrants on Exozymes. We have approximately 7.1 million shares and some warrants on Pollux. with not only, you know, core, you know, value creating, you know, readouts coming shortly and we're hoping with ExpoZines some core value creating commercial partnerships soon. We own 100% of public ventures and we own 100% of patent vests. So if you start to do the math and you start to look at, you know, through the numbers of MDB and through the balance sheet of MDB, you start to look at that and say, okay, what could those be? Well, we think that there's, you know, significant, you know, multi-billion dollar potential in things like Exozymes and Paul X.
30:58 We think there's, you know, perhaps not in the short run for public ventures and pad vests, that kind of potential. But we think there's great potential for those as well. and so when you look at how much of these we own and what it can mean and you do the math, you divide by roughly 10 million shares outstanding, you can start to realize that there's a lot of leverage embedded in MDB shares and that we certainly don't think it's being reflected in current stock price. So there's no value predictions on this page by design but I think what you'll see is we have a core belief in all of them.
31:46 Nothing's changed and we're looking to make sure that we focus on getting all these things to a value inflection point as soon as possible. I don't need to read Tony's long risk factors again but all these things, there are no sure things in life and what we want to say here is while we're super optimistic about You never know what could happen. And so the microchip market is probably, in my mind, the biggest variable that we're not in control of. And I think execution, we still have to execute on all these. We feel confident in our execution. We're working every day to make it happen. And, you know, we're super excited. So when you zoom out a bit, what we're really trying to do is protect against dilution and distribute the value, again, as we've always talked about.
32:37 Monetize or get to a value inflection is really where we're at. Not dilute MDB and distribute those things out because if we can operate on $5 to $6 million a year and we generate some fees to offset those, you know, you have an enormous amount of leverage in your ownership in MDBH. So looking at first half operations, again, that market place, Thank you for joining us. and the pipeline remains active. You know, we have a lot of really great things in the pipeline. Our quality bar is unchanged.
33:43 But some of these things, again, you really want to make sure that the backdrop is great to launch these things. So the backdrop does impact how many of these we do. And so when the backdrop is bad, you got to focus on ones that you can absolutely pound the table with impunity to get done. If you look back at the history of MDB, there's been times, I referenced Pulse Biosciences, when we did that IPO, we barely got it done. And it was a really, really, really bad time to do IPOs. And we got it done through conviction and through pounding the table. And it's provided unbelievable returns for our shareholders. So we're still going to pound the table and get life-changing things done.
34:32 But it's not like we're going to be able to get them done at the same rate while the markets are the way they are. We're looking at two transactions, could be Pollex, could be another one in the second half. So when you look at our, you know, sort of our fee income to offset expenses, you know, look to those kind of transactions in the second half of the year. We have one fee transaction that we're working on that could be quite significant, and there is a lot of leverage in what we do at MDB, and so we're hoping to surprise you with some things that we're working on that are not necessarily apparent today.
35:19 Again, I talked to the capital discipline. As we spin out PatentVest and as we partner off the clearing-offs, we can bring down our platform to about $6 million in total operational expenses that can be offset. So that's a really sort of critical number because it provides the sustainability without dilution. And that's where, as a shareholder, I'm trying to protect against and not have to sell our positions too early and wait for those key inflection points. And in some cases, if I saw an opportunity to invest more, to do more, the great news is I don't see that. What I see is that we've invested in these things.
36:15 They're ready. and the ones that are already public or about to go public are, you know, they can live on their own. And so we're excited. We think it's a sustainable thing. It's going to be lumpy. It always has been lumpy historically. Since we're not doing, you know, three to five transactions a year of new big ideas, it's, you know, it's going to be lumpy and there's no way to get around it. And I would say that that's As a public company, sometimes you have to deal with the lumpiness, unfortunately. There's sort of no way to get around it. But the underlying value, we're still very excited about. I think I pretty much covered this.
37:07 Basically, launch big ideas, operate lean, and own equity in meaningful new companies. Thank you for joining us. is, you know, everyone gets tried in these environments. And certainly, you know, whether it's employees, myself, all of us, we get tried, but we still really believe in what we're doing.
37:53 And, you know, I'm energized every day to launch these, you know, these new enterprises. So, you know, if you look at, you know, 17 IBOs over the 29 years, all of them have traded a significant premium at some time post-IPO and reached valuations enabling following capital. Again, past performance is not a guarantee of future returns, but we're highly confident that as rotation happens, our companies are going to get noticed. It is a difficult environment for micro-caps, but it's also the place if you're patient and you research your positions well, and we have Thank you for joining us.
39:06 What keeps us excited is we know that we're creating companies that make a positive difference. That's what keeps me still working today is doing what I'm doing in difficult times. We know that these companies are game-changing potential companies that really, really will make a difference. And You know, it's the only reason I do what I do today. And, you know, it's a, you know, it's an exciting time to be alive with what's happening in AI, what it's enabling for companies like, like Exozymes, like PatentVest, and others, you know, it really is, you know, one of the most transformative periods in our history. And so, We really want to thank you for being part of our community and at MGB and help, you know, driving what, you know, to make a difference in what we do and, you know, with all these companies we lost.
40:12 So with that, George, I'll open it up to you. How do I, let's see, click to exit.
40:23 Hey, look, so the first question is, can you talk a little bit about, you know, how these portfolio companies, obviously with Pat Invest and, you know, the public venture broker dealer, you have control of those. But with, let's say, Exozyme and Pollux, what are you doing to help these companies kind of recognize their full value or help them for people to know about them and learn about them? What are you doing? for portfolio companies. What impact are we having as a firm on those?
40:56 I think that what we have to offer, especially after launching, is our, you know, close to three decades of experience of how to manage it. You know, if you look at exercise is a great example. I spend, you know, we all have been spending a lot of, you know, team MDB spending a lot of time on exercise. And, you know, the markets have pivoted and changed, right? And, and, To us, it should be obvious that these guys could be, you know, finally deliver on Symbio, but we've had to pivot and say, listen, guys, let's help on commercialization. Let's, you know, let's pick up the phone. Let's actually help, you know, Exozymes, you know, secure those commercial relationships. And, you know, we, our community, us, we have a lot of relationships that can bring to bear on that. And we're doing that. We're spending real time with the team at Exozymes.
41:51 Not taking anything away from them. It's just, you know, it's all hands on deck, right? And with regard to getting recognized, we, you know, we have to really, you know, dig in and help them to, you know, translate that to the world. It's very, very difficult to conflict science. But, you know, we've spent a lot of time working with a team to simplify it and translate it. So, you take a company like Pollock, same thing. You've got the life science sector in a sense has come back a bit. Obviously the sector they're in is super exciting, super vibrant but making very tough decisions about what's the best way to go public. Do you go public with a partner on board already or do you just do the IPO before which is What Our Plan Has Been. There's a lot of real considerations in helping develop these companies and helping develop the value of these companies.
42:54 And I think connecting the dots is really the key thing for all these small companies. These small companies, there's a wall of doubt and worry that surrounds all these things, and it's really making it obvious to investors that they have the right plan to get there, right? And We spend a lot of time on that. And then, you know, just getting in front of people, right? That's what you do in the community. We've got to get them in front of people that can make a difference. I don't think that, you know, your average – we're not really an investment bank per se, even though we own one. But, you know, most investment banks are just interested in getting a transaction done and getting paid. We're interested in seeing the stock go up.
43:39 So we're redoubling our efforts. And when the markets are slow, it gives us more time as a small organization to help these companies. And so that's great. It also gives us more time to focus on the launch of PatentVest and also more time to get some sort of value-creating deal with public ventures as well. If the current market is slow and new launches are more difficult, then you focus on the ones you have and help get them there. We're a small but mighty organization in our own mind and you just got to focus.
44:24 And I think the idea behind this presentation was to say, hey, we're focusing on getting these core assets that we haven't fully realized, you know, to realization of their values.
44:40 So, you know, it's great hearing about the different companies. But as a shareholder for MDB, can you talk a little bit about what you've been doing, what you're planning to do? You know, this is a pretty good story. If you buy into the leverage here, how are you getting that story out and the message out to other shareholders so that people would join in here? with where the stock's at. What have you been up to?
45:04 Well, you know, I've been doing a few podcasts. I don't know how, you know, again, sometimes, you know, we go out and, you know, go to these conferences and what have you. But, you know, we went to the Planet Microcap, you know, conference and it's kind of a, you know, they put on a wonderful conference. I don't want to take anything away from them, but it's a little depressing to see how unpopulated these conferences are, right? We've been to two Microcap conferences and We know that waxes and wanes and changes and whatever else, but there's just not a lot of new blood there. You get out to conferences where I'm doing a few podcasts. I don't know how much reach they really have. You try and simplify and tell the story in a different way, but when your asset class is out of favor, it's challenging.
45:55 Like I said, Nothing stays constant. Everything's always changing. And so you just be consistent without informing people, getting the message spread the best you can. We talk to these family office platforms or RIA platforms. It's really interesting. What I love is people love the concept of what we're doing and they understand it from an intellectual perspective. But That's not where the money's flowing, so they're no longer putting money in private equity as much. They're no longer putting money in traditional venture as much, but they don't need to because you can buy NVIDIA and just get all the liquidity you want and make lots of money until you can't.
46:50 And so I think that that's the way I look at it, is we just stay consistent, do that work, continue to tell the thing. By the way, if anyone's got any bright ideas, we're all ears. We certainly don't believe we've got it all figured out. We rely upon our shareholders telling us what they think and what we can do.
47:19 Heartbeam didn't make your four horsemen there, but our share position on that is Small compared to the other four, obviously, but one of the questions here is what do you feel about HeartBeam right now and the technology and where the company's at?
47:38 So, you know, again, it's sort of like they have, we completely believe in their platform. It can be completely transformative. Nothing's changed. They've got the ability to put an ambulatory device, read ECG signals better than anybody. I think that they've now acknowledged that trying to launch the product on their own was not the right approach. And I think that there are plenty of people that can integrate that technology platform into their product or service category. And it's more capital efficient.
48:23 If the market is going to dilute you, You've got one of the best technologies out there. Why would you dilute your shareholders to do something that's super capital intensive at this price? And quite frankly, they don't have the team to launch the product appropriately. We try to give good counsel to them, but we don't run the company. But I think that their strategy now is the right strategy. and now they need to, whether it's work with foreign governments or work with other ECG makers, other ambulatory monitoring companies, whether it be wearables or whoever, this is, you know, this device needs to be in every airport and every airplane and every public office and every sports team. This device needs to be everywhere.
49:21 Every health clinic in the world because It's going to save millions of lives, but they have to do the partnership deals, much like exercise. It's all about partnership deals. You've got to leverage your technology platform with people that have the channels open already. I'm very happy to see they're moving in that direction. It extends their runway and enables them to get to commercialization with less dilution and so nothing's changed except, you know, the stock price is depressing. But again, for somebody that does their work and goes in there and understands it, spends some time with management and I think now that their strategy is, I think, the right strategy, this could represent an unbelievable opportunity for investors.
50:20 Back to Exazyme. Final question. If you have a question, go ahead and hit that Q&A button down at the bottom of the screen and type it in. We've got time for one or two more questions. Regarding Exazyme's financing, they were hoping to raise a lot more money, ended up raising around $6 million. Can you kind of characterize the challenges? I think you kind of have already, but you might want to re-summarize kind of where they were at and where they're going.
50:46 You want to manage dilution. Again, they're also capital efficient. They have huge asymmetric upside. They're OpEx, you know, depending on grants or whatever, around $10 million a year. And I think that one of the things that we've talked about is you know, if NCT becomes its own platform that's funded separately, that becomes a real, not only value-paying event, but also lessens the capital needs of developing NCT. But I think there's other molecules that they can do deals on as well. So, you know, I think that you could see strategic investments, you could see you know, spin-offs that help fund things that are non-dilutive, right?
51:31 That actually create value. Not promising those things. I'm just saying that I know those are things that they're working on and that could happen. And I think once you get to a value inflection point by these commercial deals happening, these offerings become less dilutive. And more importantly, it becomes easy to do a financing once people clearly see that this thing is going to be commercial and it's no longer just a technology platform. And I think that, you know, As soon as we see those commercial deals happen, I think people are going to get it.
52:06 Okay, well, we're going to go ahead and wrap it up. Tony, do you have any closing comments before Chris wraps up? No, George. I think if that's all we've got for today, we just want to say again, thank you for attending, and this will wrap up today's call.
52:24 Thanks, everyone.
Follow MDB Capital Holdings, LLC into a list and get an email when it puts out news.
Chief Executive Officer and Co-Founder
President and Head of Community Development